KARYOPHARM THERAPEUTICS INC. NON-QUALIFIED STOCK OPTION AGREEMENTNon-Qualified Stock Option Agreement • September 5th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This option satisfies in full all commitments that the Company has to the Optionee with respect to the issuance of stock, stock options or other equity securities.
Consulting AgreementConsulting Agreement • September 5th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement, dated effective October 28, 2010 (this ‘“Agreement”), is made and entered into by and among Karyopharm Therapeutics, Inc., a Delaware corporation with offices at 15 Bontempo Rd., Newton, MA 02459 (the “Company”) and Alan T. Barber doing business as the Prestar Group at 134 Alcott Rd, Concord, MA 01742 (the “Consultant”).
CONSULTING AGREEMENTConsulting Agreement • September 5th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
THIS CONSULTING AGREEMENT (the “Agreement”), made this 1st day of September, 2012 is entered into by Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), and Mirza Consulting, a Denmark company with its principal place of business at Måløvgårdsvej 23, 2750 Ballerup, Denmark (the “Consultant”).
COMMERCIAL LEASE DATED AS OF DECEMBER 10, 2010 BETWEEN NIVEK INVESTMENTS I, LLC AND KARYOPHARM THERAPEUTICS, INC. SUMMARY OF BASIC TERMSCommercial Lease • September 5th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
The following is a summary of certain basic terms of this Lease which is intended for the convenience and reference of the parties. In addition, some of the following items may be incorporated into the Lease by reference to the “Summary of Basic Terms”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. RESEARCH AGREEMENTResearch Agreement • September 5th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • New York
This Research Agreement (this “Agreement”) is made as of the 18th day of July, 2011 (the “Effective Date”) by and between The Multiple Myeloma Research Foundation, Inc., a Connecticut non-stock corporation, with its principal place of business at 383 Main Avenue, 5th floor, Norwalk, CT 06851 (“MMRF”) and Karyopharm Therapeutics Inc., a Delaware corporation, with its principal place of business at 2 Mercer Road, Natick, MA 01760 (“Company”). MMRF and Company are sometimes hereinafter referred to individually as the “Party” and together as the “Parties”.
KARYOPHARM THERAPEUTICS INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT July 26, 2013Adoption Agreement • September 5th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 26th day of July, 2013, by and among Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor”, and the Founders (as defined below).
